[ Price : $8.95]
FDA grants X4 Pharmaceuticals a breakthrough therapy designation for mavorixafor for the treatment of adult patients with WHIM (Wa...[ Price : $8.95]
FDA places a clinical hold on a Marker Therapeutics planned Phase 2 study of its MultiTAA T-cell therapy in post-allogeneic hemato...[ Price : $8.95]
Researchers call on FDA to update guidances on endpoints for developing anti-infective drugs.[ Price : $8.95]
The Hill reports the Trump administration is proposing to lower some drug prices by ensuring that prices in this country are lower...[ Price : $8.95]
Eye on FDA notes a reduction in the number of drug-related advisory committee meetings this year and whether this can be seen as l...[ Price : $8.95]
The Stericycle Expert Solutions third quarter recall index shows a lower number of prescription drug recalls and a very high numbe...[ Price : $8.95]
Braeburn says its Brixadi treatment for opioid use disorder is available to be marketed 12/1/20 after FDA revoked the orphan drug ...[ Price : $8.95]
FDA issues a guidance explaining the process to seek review of a Certificate to Foreign Government denial.